NormOxys Obtains $17,500,000 Series B Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    16 Laurel Ave. Wellesley, MA 02481
  • Company Description
    NormOxys is developing a novel class of small molecule drugs, oxyrens, which enhance the body’s ability to deliver oxygen more efficiently to diseased tissues with oxygen deficiency. This new class of drugs can be potentially developed in a broad range of clinical indications where therapeutic benefit can be obtained through an increased, regulated delivery of oxygen to hypoxic tissues, such as cancer, cardiovascular diseases, anemia, stroke and diabetic retinopathy.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will enable NormOxys to advance its lead drug candidate, OXY111A, into clinical development in 2010 in two diseases, chronic heart failure and cancer, and complete clinical studies through proof-of-concept in both of these indications.
  • M&A Terms
  • Venture Investor
    Care Capital
  • Venture Investor
    Index Ventures
  • Venture Investor
    Index Ventures

Trending on Xconomy